Lunch Panel: A Cure for What Ails Us: Celebrating the Impact of Science (updated II)

Historical Context and Bioscience Impact

• Worldwide life expectancy rose from 26 years in 1800 to 31 years by 1900, driven by improved sanitation.
• The 20th century saw a sharp drop in infectious diseases due to over two dozen vaccines and antibiotics.
• Life expectancy in the US jumped to 49 years by 1950 following major medical advancements.
• The Human Genome Project (1990–2003) cost $3.8 billion over 13 years and revolutionized the diagnosis and treatment of over 4,000 genetic diseases.
• The economic impact of the Human Genome Project exceeded its original investment by creating thousands of jobs.
• Current global life expectancy is 67 years, with US life expectancy near 80 years.

Current Challenges in Scientific Funding and Infrastructure

• The US has made an incremental $200 billion investment in bioscience federal agencies since March 1998.
• Adjusted for inflation, US investment in biosciences has decreased over the last decade despite flat budgets.
• NIH grant success rates have plummeted from an average of 33% over 50 years to under 20% in the last 10 years.
• Recent sequestration cuts of $1.7 billion in a single month reduced new applicant success rates to approximately 10% or lower.
• Young scientists face reduced funding opportunities despite the majority of historic discoveries (e.g., Einstein, Newton) coming from individuals within five to ten years of their education.
• The US is now the heaviest country among developed nations, with obesity-related issues affecting all states.
• The cost of obesity and poor lifestyle choices in the US is estimated at $1 trillion annually.

Specific Disease Progress and Case Studies

• Polio: Global cases dropped from 350,000 in 1988 to 223 in 2012, with the disease now endemic in only three countries.
• AIDS: The PEPFAR program, initiated under the Bush administration, currently treats 5.3 million people worldwide.
• HIV Prevention: PEPFAR has prevented more than 250,000 babies from being born with HIV in the last year alone.
• Cystic Fibrosis: A 23-year gap (1989–2012) existed between identifying the genetic cause and FDA approval of the first targeted drug, Kalydeco.
• Cystic Fibrosis Success: Kalydeco is effective for the 4–5% of patients with a specific gene mutation; two additional drugs in trials aim to treat 90% of patients.
• Alzheimer's: New genetic factors beyond ApoE have been identified, along with pathways involving immunology and lipid metabolism.
• Brain Initiative: A multi-agency partnership (NIH, NSF, DARPA, private foundations) has been launched to map the 86 billion neurons in the human brain as a decade-long effort.

Public Health and Pandemic Preparedness

• H7N9 Avian Flu: In China, H7N9 has a high mortality rate of approximately 20% but currently has limited person-to-person transmission capability.
• CDC Capabilities: The CDC's Strategic National Stockpile can deploy emergency medical supplies to any US location within 12 hours.
• Vaccine Distribution: During the 2009 H1N1 pandemic, the CDC distributed 320,000 vaccine shipments to over 80,000 doctors without logistical errors.
• Global Surveillance: Collaborative efforts with China over 10 years enabled the rapid identification and international sharing of the H7N9 virus sequence.
• Measles: Immunization efforts in the last decade prevented four million child deaths annually, though imported cases remain a risk in the US.
• Universal Flu Vaccine: Clinical trials are exploring vaccines targeting the invariant hemagglutinin stem to provide broad, long-term protection against all influenza strains.

Cardiovascular Health and Lifestyle Trends

• Heart Disease: Deaths from heart disease in the US have decreased by 36% over the past decade due to scientific advances.
• Ideal Health Metric: Fewer than 1% of Americans currently meet the American Heart Association's criteria for "ideal cardiovascular health."
• Risk Factor Correlation: Men reaching age 50 with ideal cardiovascular health have a lifetime heart attack risk of less than 5%.
• Diabetes Link: Type 2 diabetes is a primary risk factor for cardiovascular events, driven in part by high-fat and high-sugar food trends.

Strategic Priorities and Future Directives

• Drug Development Reform: The NIH has established the National Center for Advancing Translational Sciences (NCATS) to reduce the 14-year average drug development timeline and high failure rates.
• Regenerative Medicine: Focus is placed on 3D printing and stem cell technology to regenerate cardiac and kidney tissue, potentially reducing transplant needs.
• Precision Medicine: The cost of whole-genome sequencing has dropped from billions to a few thousand dollars, enabling personalized treatment plans.
• STEM Pipeline: There is an urgent need to maintain funding and interest in STEM education to prevent a skills gap in the bioscience workforce.
• Global Collaboration: FDA offices have been opened in China, India, Central America, and the Middle East to build international regulatory capacity and data sharing.
• Economic Justification: Bioscience investments account for more than 50% of US economic growth since World War II.
• Prevention vs. Treatment: 90% of current health spending goes to treatment and care, creating a strategic imperative to shift resources toward wellness and prevention.